|
|
4 April 2019 |
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that it was notified on 1 April 2019 that on the same day, Chris Meredith, who is a Director and PDMR, had sold 5,735 Ordinary Shares of 5p held on his behalf in the name of Platform Securities Nominees Limited (“CM’s Nominee”) at a price of 318p per Ordinary Share. AMS was also notified that on 1 April 2019 that on the same day, Chris Meredith’s PCA had sold 4,850 Ordinary Shares of 5p held on their behalf in the name of Platform Securities Nominees Limited (“PCA’s Nominee”) at a price of 318p per Ordinary Share.
On the same day, Chris Meredith purchased 5,735 Ordinary Shares of 5p through an Individual Savings Account held in his name at a price of 318.25p per Ordinary Share. The Company was also informed that at the same time an Individual Savings Account held in the name of Chris Meredith’s PCA purchased 4,850 Ordinary Shares of 5p at a price of 318.25p per Ordinary Share.
The number of shares, and the beneficial ownership of the shares, held by Chris Meredith and his PCA’s remains unchanged. These transactions are part of normalised tax planning.
The transactions are summarised below:
|
Director |
Number of Ordinary Shares sold from Nominee |
Price per Ordinary Share sold |
Number of Ordinary Shares purchased by an Individual Savings Account |
Price paid per Ordinary Share by an Individual Savings Account |
Number of Ordinary Shares purchased by an Individual Savings Account |
Price paid per Ordinary Share by an Individual Savings Account |
|
Chris Meredith |
5,735 |
318p |
5,735 |
318.25p |
– |
– |
|
Chris Meredith |
4,850 |
318p |
– |
– |
4,850 |
318.25p |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Chris Meredith |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: Director/PDMR |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Sale of 5,735 Ordinary Shares of 5p held in the name of CM’s Nominee · Purchase of 5,735 Ordinary Shares of 5p by an Individual Savings Account held in the name of Chris Meredith |
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 5,735 Aggregated price: 318p |
||||||
|
e) |
Date of the transaction: 01/04/2019 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Chris Meredith |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: Director/PDMR |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Sale of 4,850 Ordinary Shares of 5p held in the name of the PCA’s Nominee · Purchase of 4,850 Ordinary Shares of 5p into an Individual Savings Account held in the name of Chris Meredith’s PCA |
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 4,850 Aggregated price: 318p |
||||||
|
e) |
Date of the transaction: 01/04/2018 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
– End –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: 44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: 44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: 44 (0) 20 7597 5970 |
|
Daniel Adams / Gary Clarence / Patrick Robb |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include tissue adhesives, sutures, biosurgical devices, internal sealants, silver alginates, alginates and foams, which it markets under its brands; LiquiBand®, LiquiBand® Fix 8™, RESORBA® and ActivHeal® as well as supplying under white label.
AMS‘s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 630 employees. For more information, please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHGCGDSXBGBGCS